|
|
Translation
2007 - Isomark, LLC This company is based on WARF patents developed by the founders for the early detection of infectious disease using biomarkers in breath. Scientist from UW-Madison founded Isomark, LLC including METC faculty Mark Cook, PhD and Warren Porter, Phd. Isomark's patented technology offers a unique non-invasive method for rapid detection of invasive infections. Goal is to assist healthcare providers achieve a critical need for earlier and more accurate diagnostic techniques.
2005 - Functional Biosciences is a microfluidics company developed by Christopher A. Bradfield, PhD. This company uses proprietary technology developed to perform genomic analyses in nanoliter volumes. The company currently offers a line of genomics services and is developing the technology for toxicogenomics applications.
2004 - Mithridion Inc. - Established 2004 based on UW-Madison research in the Jeffrey A. Johnson, PhD. A biopharmaceutical company that discovers and develops drugs for neurodegenerative diseases, with a focus on Alzheimer’s disease. Mithridion has exciting drug leads with neuroprotective properties at the heart of its drug design and development program. These leads are being synthesized and modified by Mithridion’s medicinal chemists to build in the desired drug properties, such as dosage route and duration of action.
2001 - AovaTechnologies Inc. - Company is based on antibodies for improving animal growth. Successor of company based on novel process of producing egg antibodies to prevent the collateral damage of immune responses, developed initially in the lab of Mark E. Cook, PhD in Animal Sciences. Aova Technologies is an agricultural biotechnology company and offers producers and feed nutritionist strategy in animal nutrition.
2000 - Stratatech Corporation - founded in 2000 by B. Lynn Allen-Hoffmann, PhD, is a regenerative medicine company focused on the development of cell-based, tissue-engineered products for wound care. The keystone of Stratatech's approach is a proprietary human skin cell line that when properly cultured forms a fully stratified multi-layered human tissue with the physical strength and biological characteristics of intact human skin. This biologically active tissue is suitable for transplantation on patients using traditional surgical suturing techniques. Stratatech is developing new products that have been genetically enhanced to over-express natural, human wound-healing factors that reduce infection, improve blood flow to the wound, and increase the rate of healing with reduced scarring. The company has generated the first engineered human tissue in the history of the state and is the first company founded by a woman scientist at the University of Wisconsin. Stratatech has assembled a team of experienced research, production, clinical, and regulatory personnel to facilitate the discovery, development, and commercialization of their products.
1997 - Mark E. Cook, PhD was a minor founder in Conlinco which was bought out by BASF The Chemical Company. Conlinco specializes in a nutritional and dietary ingredient , CLA, or conjugated linoleic acid, for feeding to humans as a dietary supplement/ingredient and feed additive for animals feeds. The company was founded in 1997 with the intent of developing CLA for animal feed ingredients and for functional foods.
|
